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Introduction
Femoral artery access remains the most commonly used arterial access during coronary angiography and intervention despite an increase in radial procedures. 1, 2 Femoral access complications remain infrequent, ranging from ,1% to 17% of procedures. [3] [4] [5] [6] [7] It is not uncommon to see patients presenting to the cardiac catheterization laboratory on oral anticoagulant (OAC) fully or partially anticoagulated and undergoing common femoral artery (CFA) access. 8 Several new OAC (NOACs; oral Xa and thrombin inhibitors) have emerged within the past 3-6 years and are now an alternative to warfarin in treating patients with nonvalvular atrial fibrillation or venous thromboembolic 
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shammas et al disease. 9 Some data suggest that coronary procedures can be performed safely with uninterrupted OAC at the time of the index procedure. 10 In this study, we investigated whether orally anticoagulated patients have a higher risk of femoral access site complications when compared to patients who are not anticoagulated with OAC during coronary procedures.
Methods
We retrospectively reviewed data from 779 consecutive patients who underwent a cardiac procedure (diagnostic or interventional) at a tertiary medical center. Patients were identified from the cardiac catheterization procedural log. Medical records were reviewed by dedicated research assistants, and data entry was audited by a Clinical Research Associate. The study was approved by the Genesis Health System Institutional Review Board at the medical center. Informed consent by patients to review their medical records was waived by the same institutional review board due to the retrospective nature of the study and the large number of patients included that made it impractical or impossible to obtain informed consent from patients. All investigators signed a patient confidentiality agreement with the medical center.
Patients were considered (group A) fully or partially anticoagulated if they had an international normalized ratio (INR) $1.6 on the day of the procedure or were on warfarin or NOAC within 48 h and 24 h of the procedure, respectively. The nonanticoagulated group (group B) had an INR ,1.6 or have stopped their warfarin and NOAC .48 h and .24 h preprocedure, respectively. Non-CFA and bilateral CFA accesses were excluded. Radial procedures were excluded as they are performed infrequently in our medical center.
The index primary end point of the study was defined as the composite end point of major bleeding, vascular complications (arteriovenous (AV) fistula or pseudoaneurysm), or cardiovascular death during index hospitalization. The 30-day primary end point was defined as the occurrence of the index primary end point and up to 30 days postprocedure. Other secondary end points included the following major adverse events: major bleeding, total death, cardiac death, vascular complications, including AV fistula and pseudoaneurysm, stroke (hemorrhagic or embolic), and myocardial infarction. Demographic, clinical, and procedural angiographic variables were collected (Table 1) .
Major bleeding was defined as a drop of 3 units of hemoglobin or transfusion of 2 units of blood with a clear 
Results
Demographic and clinical characteristics
A total of 779 patients were included in this study (mean age 65.6±12.2 years, males 62.4%). Of these patients, 27 (3.5%) patients were in group A. In bivariate analysis (Table 3) , the 30-day primary end point was significantly associated with female gender (P=0.0481), weight ,60 kg (P=0.0040), low hemoglobin at baseline (P=0.0410), reduced CrCl (P=0.0001), high activated clotting time (ACT) (P=0.0150), high intraprocedural heparin dose (units per kg; P=0.0110), and high BMI (P=0.0040) but not group A versus group B. There was also no association between the type of coronary procedure done (cardiac catheterization vs intervention) and the primary adverse event at the time of the procedure (0.95% and 1.72%, respectively, P=0.5393) or at 1 month (P=1.000). However, patients who underwent an intervention in group B had a higher primary adverse event at 1 month when compared to cardiac catheterization patients in group B. 
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Predictors of CFa access site complications a radial approach in reducing postcardiac procedure complications. 17 However, studies have shown that patients with uninterrupted warfarin undergoing radial approach had less vascular complications. 18, 19 In this study, univariate analysis indicated that the higher the units per kilogram of unfractionated heparin administered intraprocedurally, the higher the primary composite adverse end points. Intraprocedural antithrombotic therapy has been shown to increase the risk of vascular complications in patients who are on warfarin irrespective of the degree of anticoagulation. 20 Multivariate analysis, however, showed that intraprocedural heparin, when adjusted for CrCl and underweight patients (,60 kg), did not predict adverse events. The presence of renal failure is a strong predictor of adverse events postcardiac intervention. 21, 22 In a study of 8,521 patients evaluating the relationship between glomerular filtration rate (GFR) and all-cause mortality, there was a decline in survival postcatheterization that correlated with a decline in GFR. In this study, for every 10-unit decrease in GFR, there was ~17.2% relative increase in mortality risk. This is consistent with the findings in this study that showed that an increase in CrCl reduces the likelihood of occurrence of the 30-day composite end points of major bleeding, vascular complications, and cardiovascular death (OR 0.56). Also, several studies have shown that a high or low BMI correlate with vascular complications. [3] [4] [5] 7 In our study, a low weight of ,60 kg was an independent predictor of complications in orally anticoagulated patients.
A lower preprocedural hemoglobin, OAC, a longer procedure time, and an urgent/emergent procedure independently predicted the combined 30-day adverse events (major bleeding, cardiac and noncardiac death, stroke, myocardial infarction, and vascular complications). These events are driven by death, myocardial infarction, and stroke and likely reflect a high-risk patient population with more unstable symptoms and requiring prolonged procedures. 23, 24 Limitation of the study This is a retrospective study and therefore selection bias cannot be ruled out. This, however, was addressed by including all consecutive patients with the exception of excluding those with bilateral CFA and non-CFA access sites (small number of patients in our center). Therefore, data in this study do not apply to radial procedures. Radial access appears to be safe in patients actively on anticoagulation and is now becoming more widely adopted in the US. Finally, this study needs to be verified in a larger registry of patients on anticoagulation as the overall number of anticoagulated patients in this study is relatively small and with low number of patients reaching end points. 
Discussion
Adverse events during index coronary angiography occurred in 3.7% of patients. This is within the reported range of access site complications. In multivariate analysis, irrespective of the intraprocedural anticoagulant, patients with uninterrupted anticoagulation with OAC did not have an increase in the composite primary end point of major bleeding, vascular complications (AV fistula or pseudoaneurysm), or cardiovascular death during their index hospitalization and up to 30 days when compared to patients who were not anticoagulated with OAC. These data, however, do not apply to patients who receive lytic therapy (as none of our patients had received a thrombolytic) or GPIIb/IIIa inhibitors (,1% of patients in our cohort). 11 Furthermore, these data are in the setting of the majority of patients receiving a closure device and, therefore, cannot be extended to those who undergo hemostasis with manual compression. There are conflicting data on the value of vascular closure devices in reducing complications postfemoral arterial access in patients undergoing cardiac procedures. [12] [13] [14] [15] Recent data, however, seem to favor closure devices in reducing complications postcardiac diagnostic or interventional procedures. 14, 15 Finally, no radial approach patients were included in this study (limited use of radial in our laboratory). Recent studies have shown that both radial and femoral approaches were safe after percutaneous coronary intervention but a radial approach had less vascular complications. 2, 16 On the other hand, a femoral approach with vascular closure device (Angioseal) was noninferior to
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Conclusion
Independent predictors of the combined end points of major bleeding, vascular complications, or cardiovascular death at index or up to 30 days in patients undergoing coronary procedures are low weight (,60 kg) and renal insufficiency but not OAC. These conclusions are limited to patients undergoing femoral vascular access and not receiving GPIIb/IIIa inhibitors or lytic therapy.
